Twist Bioscience Corporation announced its fiscal fourth quarter and full year 2024 financial results on November 18, 2024, reporting a fourth-quarter loss per share of 59 cents, which beat the consensus loss of 70 cents. Fourth-quarter sales reached $84.71 million, marking a 27% increase year-over-year, surpassing both the consensus of $82.2 million and management's guidance of $82 million–$83 million.
The company shipped products to approximately 3,562 customers in fiscal 2024, an increase from 3,450 in 2023, and shipped approximately 772,000 genes in 2024, up from 634,000 genes a year ago. Total orders received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period in fiscal 2023, demonstrating robust demand.
Gross margin improved significantly to 45.1% from 36.6% a year ago, and adjusted EBITDA for the quarter was $(17.0) million, an improvement from $(26.4) million in Q4 FY23. For fiscal year 2025, Twist Bioscience provided guidance projecting total sales between $367 million and $377 million, representing 17%–20% year-over-year growth, with an expected gross margin of approximately 48% and adjusted EBITDA between $(60) million and $(65) million. The company also guided for Q1 FY25 sales of approximately $87 million, exceeding the consensus of $84.47 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.